Development and validation of a UPLC–MS/MS method for the novel folate-targeted small molecule drug conjugate EC1456 and its metabolites in tumor homogenates from mice
- 1 April 2016
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 122, 148-156
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Chemistry and biology of tubulysins: antimitotic tetrapeptides with activity against drug resistant cancersNatural Product Reports, 2015
- Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenateJournal of Pharmaceutical and Biomedical Analysis, 2015
- Tissue Bioanalysis of Biotherapeutics And Drug Targets to Support Pk/PdBioanalysis, 2012
- The Pharmacokinetic/Pharmacodynamic Pipeline: Translating Anticancer Drug Pharmacology to the ClinicThe AAPS Journal, 2011
- Quantitative analysis of PD 0332991 in xenograft mouse tumor tissue by a 96-well supported liquid extraction format and liquid chromatography/mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2010
- In Vivo Structural Activity and Optimization Studies of Folate−Tubulysin ConjugatesMolecular Pharmaceutics, 2009
- Tissue concentrations: do we ever learn?Journal of Antimicrobial Chemotherapy, 2007
- Mechanism of Action of Tubulysin, an Antimitotic Peptide from MyxobacteriaChemBioChem, 2006
- Tubulysins, New Cytostatic Peptides from Myxobacteria Acting on Microtubuli. Production, Isolation, Physico-chemical and Biological Properties.The Journal of Antibiotics, 2000
- Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implicationsCancer, 1994